Navigation Links
UFE Highly Effective in Cases Where Focused Ultrasound to Treat Uterine Fibroids Failed

Significant Relief of Symptoms Noted From Uterine Fibroid Embolization

WASHINGTON, March 18 /PRNewswire-USNewswire/ -- Uterine fibroid embolization (UFE), a minimally invasive interventional radiology treatment for uterine fibroids, provides significant relief of symptoms for women whose focused ultrasound (FUS) treatment failed, according to a study released today during the Society of Interventional Radiology's 33rd Annual Scientific Meeting in Washington, D.C. Primary care physicians and gynecologists can feel confident in informing patients that a failed FUS treatment does not require subsequent gynecological surgery. Those women can be successfully treated with UFE. Patients with a single large fibroid are candidates for FUS; patients with many fibroids, which is more often the case, would be better treated with UFE. There is limited long-term follow-up data for FUS and limited information on fibroid recurrence rates. In this retrospective study from Boston's Brigham and Women's Hospital, seven post-FUS patients who experienced therapeutic failure and were subsequently re-treated with UFE were reviewed. In all patients, their symptoms -- such as heavy menstrual bleeding and the sensation of fullness or pressure in the lower abdomen -- improved.

"FUS is a newer procedure for uterine fibroids and whether it provides sustained symptom relief is still being evaluated. My research shows that when FUS fails, these women could benefit from uterine fibroid embolization," said Alisa Suzuki, M.D., interventional radiologist at Brigham and Women's Hospital.

Uterine fibroids are noncancerous (benign) growths that develop in the muscular wall of the uterus and are treated only if they are causing bothersome symptoms. With UFE, an interventional radiologist inserts a catheter into the femoral artery and using real-time imaging, guides the catheter up the artery and then releases tiny particles, the size of grains of sand, into the uterine arteries that supply blood to the fibroid tumor. This blocks the blood flow to the fibroid tumor and causes it to shrink and die. FUS focuses high-frequency, high-energy sound waves to generate heat at a specific point within the fibroid tissue to shrink the fibroid and relieve symptoms. FUS has been approved by the Food and Drug Administration (FDA) for several years. Due to the limited number of institutions providing FUS, the number of procedures performed is still limited.

"Today, women have more options. Fibroids will not kill a patient, but they could ruin her lifestyle. UFE is widely available; patients can easily obtain information about this interventional radiology treatment on the Internet. Women should ask for a consult with an interventional radiologist who can determine from MRI imaging whether they are candidates for either procedure. We have experience in treating fibroids, access to exciting new technologies and are happy to discuss various options with patients," said Suzuki.

Abstract 142, "When Sound Fails: Efficacy of Uterine Artery Embolization for Focused Ultrasound Surgery Therapeutic Failures," can be found at

About Uterine Fibroid Embolization

Uterine fibroids are very common noncancerous (benign) growths that develop in the muscular wall of the uterus. They can range in size from very tiny (a quarter of an inch) to larger than a cantaloupe. Occasionally, they can cause the uterus to grow to the size of a five-month pregnancy. In most cases, there is more than one fibroid in the uterus. Uterine fibroids can cause prolonged, heavy menstrual bleeding that can be severe enough to cause anemia or require transfusion, disabling pelvic pain and pressure, urinary frequency, pain during intercourse, miscarriage, interference with fertility and an abnormally large uterus--resembling pregnancy.

Twenty to 40 percent of women age 35 and older have uterine fibroids of a significant size. African American women are at a higher risk for fibroids: as many as 50 percent have fibroids of a significant size. Uterine fibroids are the most frequent indication for hysterectomy in premenopausal women and, therefore, are a major public health issue. Of the 600,000 hysterectomies performed annually in the United States, one-third are due to fibroids.

About the Society of Interventional Radiology

Interventional radiologists are physicians who specialize in minimally invasive, targeted treatments. They offer the most in-depth knowledge of the least invasive treatments available coupled with diagnostic and clinical experience across all specialties. They use X-ray, MRI and other imaging to advance a catheter in the body, usually in an artery, to treat at the source of the disease internally. As the inventors of angioplasty and the catheter-delivered stent, which were first used in the legs to treat peripheral arterial disease, interventional radiologists pioneered minimally invasive modern medicine.

Today many conditions that once required surgery can be treated less invasively by interventional radiologists. Interventional radiology treatments offer less risk, less pain and less recovery time compared to open surgery. Visit

Local interviews, medical illustrations and broadcast-quality video footage are available for UFE by contacting SIR's communications department at A UFE fact sheet and statistics can be found in the Media section at

SOURCE Society of Interventional Radiology
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Consumer Specialty Products Association Highly Critical of NRDC Study on Home Air Fresheners
2. 454 Sequencing(TM): Science Paper Describes a Novel, Highly Efficient Method of Sequencing Ancient DNA; Sequences the Mitochondria of 10 Individual Mammoths to Prove It
3. 18F-DG PET/CT can highly increase the detection of colorectal cancer
4. Plastic Surgery Complications and Deaths are Rare, Despite Highly Publicized Death of Donda West
5. CT angiography highly accurate, multicenter trials show
6. CT Angiography Highly Accurate: Multicenter Trials Show
7. SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor
8. Highly Promising Dutch Research Into Alzheimers Disease and Parkinsons Disease
9. Songbirds offer clues to highly practiced motor skills in humans
10. LASIK works well, according to long-term study of highly myopic patients
11. Researchers find less invasive, highly accurate methods
Post Your Comments:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... District , the only authorized OSHA Training Institute Education Center headquartered in Northern ... protecting their workers from extreme heat at their worksites. Employers with workers ...
(Date:6/27/2016)... ... 2016 , ... "FCPX editors can now reveal their media with growing colorful ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Color brings the ... can now reveal the media of their split screens with growing colorful panels. , ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... announced today its affiliation with Tennessee Counseling Association. This new relationship ... of the Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... strategic partnership with Connance, a healthcare industry leader providing predictive analytics to ... technology combine to provide health systems, hospitals and ambulatory surgical centers with ...
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is ... emergency ambulance transport experience for the millions of people who require these medical ... the taxi industry through the use of technology. Now, SmartEMS has put forth ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... -- One of Australia,s successful biotechnology scientists, ... new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). ... list on the ASX. Noxopharm is a clinic-ready company ... Phase 1 clinical study later this year. ... biggest problems facing cancer patients - the ability of cancers to ...
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/26/2016)... 2016  VMS Rehab Systems, Inc. ( ) ... measures required to build a strong and stable market ... listed on the OTC Markets-pink current trading platform. ... "We are seeing an anomaly in market trading activities ... by the Company, but shareholders and market players as ...
Breaking Medicine Technology: